Aurinia Pharmaceuticals (AUPH) Tops Q3 EPS by 7c ; Offers Guidance

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q3 EPS of $0.23, $0.07 better than the analyst estimate of $0.16. Revenue for the quarter came in at $73.47 million versus the consensus estimate of $67.7 million.

GUIDANCE:

Aurinia Pharmaceuticals sees FY2025 revenue of $260-270 million, versus the consensus of $270.5 million.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• Yalla Group Limited (YALA) Reports Q2 EPS of $0.24
• Datavault AI to acquire CyberCatch for $94.5M in all-cash deal